Business Context and Reporting Period
This Form 8-K was filed by Recursion Pharmaceuticals, Inc. (RXRX) on December 3, 2024, reporting events occurring on December 2, 2024. The filing addresses the appointment of Ben Taylor as Chief Financial Officer (CFO) and President of Recursion UK, following the company's acquisition of Exscientia plc on November 20, 2024.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation arrangements.
- Base Salary: £400,000 per year.
- Annual Cash Bonus Target: 25% of base salary.
- Annual Equity Bonus Target: 25% of base salary.
- Expected Equity Grant: Aggregate value of $5,000,000 (comprising $2,500,000 in restricted stock units and $2,500,000 in stock options), vesting over four years.
Material Changes
The primary material change is the formalization of Ben Taylor's role and compensation package as CFO. Additionally, the filing details the treatment of "Exchanged Awards" (options and RSUs received from Exscientia plc during the acquisition). These awards retain their existing vesting terms but include an acceleration provision: 100% of these awards will fully vest if Mr. Taylor's employment is terminated without "cause" or if he resigns for "good reason" within twelve months following the November 20, 2024 Closing Date.
Guidance, Outlook, and Risks
The filing contains no financial guidance or market outlook. Key contingencies and terms include:
- Approval Requirement: The $5,000,000 equity grant is subject to approval by the Board of Directors or the Compensation Committee.
- Severance and Notice: Mr. Taylor is entitled to three months' advance notice or payment in lieu thereof. Garden leave or pay in lieu of notice will offset severance benefits under the Executive Change in Control and Severance Plan.
- Documentation: The full employment letter will be filed as an exhibit to the Company's 2024 Form 10-K.
Investor Verification Checklist
- Verify the final approval of the $5,000,000 equity grant by the Board or Compensation Committee.
- Review the full text of the employment letter upon its filing as an exhibit to the 2024 Form 10-K for complete terms.
- Monitor the vesting schedule of the new equity awards and the specific conditions for the acceleration of Exchanged Awards.
- Confirm the integration of Recursion UK and Exscientia AI Ltd. operations under the new leadership structure.